Pure Greeen Pharmaceuticals

Executive Summary

Pure Green Pharmaceuticals is a US-based private biotech company founded in 2018 and headquartered in Denver, Colorado. The company is dedicated to developing cannabis-based pharmaceuticals, with a lead program centered on water-soluble, sublingual CBD tablets for chronic pain management. Its primary target indications are diabetic neuropathy and osteoarthritis, two large and underserved markets where current treatments often have limited efficacy or significant side effects. By leveraging a novel water-soluble formulation, Pure Green aims to improve the bioavailability and onset of action of CBD, potentially offering a non-opioid alternative for pain relief. The company is committed to rigorous scientific development and plans to advance its candidate through FDA-regulated clinical trials. Despite the promising therapeutic potential of CBD for pain, Pure Green faces significant challenges common to early-stage biotech firms. The company is pre-revenue and has not disclosed total funding or valuation, suggesting it is likely still in the preclinical or early clinical stage. The cannabis-derived pharmaceutical space is crowded and fraught with regulatory hurdles, including varying state and federal laws in the US. However, if Pure Green can successfully demonstrate safety and efficacy in clinical trials, its water-soluble CBD tablets could capture a niche in the analgesic market. Success will depend on financing, clinical execution, and regulatory clarity.

Upcoming Catalysts (preview)

• TBDInitiation of Phase 1 Clinical Trial for CBD Tablet in Diabetic Neuropathy40% success
• TBDPre-IND Meeting with FDA60% success
• TBDStrategic Partnership or Licensing Deal for CBD Pain Platform25% success